Why is Elevance Health (ELV) stock up today?

Elevance Health shares climbed 1.20% to $430.33 on July 14, 2026, buoyed by a wave of analyst price target upgrades published in the 24 hours before the company's Q2 2026 earnings report scheduled for July 15. Wells Fargo raised its target dramatically — from $391 to $492 — while maintaining an Overweight rating, and TD Cowen lifted its target from $400 to $465 with a Buy rating. Truist also raised its target from $450 to $475, keeping its Buy rating. Mizuho nudged its Outperform target higher from $465 to $470. These upward revisions signal that several analysts see the stock as undervalued relative to their expectations heading into earnings.

The consensus of analyst moves is notable because the backdrop for health insurers has been challenging. Zacks noted ahead of the report that Health Benefits segment weakness could weigh on Q2 results, and Barron's flagged the earnings as the next major test for health insurer stocks broadly. Jefferies, while maintaining a Buy rating, only edged its target up marginally from $391 to $393 — a more cautious stance that reflects lingering uncertainty about medical cost trends in the sector.

In the most recent quarter already reported, Elevance posted earnings per share of $12.58 against an estimate of approximately $10.81, a meaningful beat. Revenue came in at $49.49B. That prior outperformance may be lending some confidence to bulls heading into the Q2 print, though earnings growth on a trailing basis is down 16.8% year-over-year, underscoring real headwinds in the business.

The broader market provided a mild tailwind, with the S&P 500 up 0.16% and the Nasdaq (QQQ) up 0.94% on the day. Macro attention was also on the July 14 CPI release, which showed cooling inflation trends. As of mid-session, Elevance shares trade in a day range of $428.46 to $432.00, with the stock sitting at a trailing price-to-earnings ratio (P/E, a valuation measure comparing share price to annual profit) of 17.6 and a forward P/E of 14.5.